改进型吸入性黏液溶解剂治疗气道黏液阻塞性疾病
该研究旨在阐明N-乙酰半胱氨酸(NAC)的药理局限性,并在临床前模型中测试新型黏液素降解剂P3001。结果显示,P3001在体外和βENaC过表达小鼠中均能显著减少肺黏液负荷,而NAC无效;在CF患者痰液中P3001起效更快、浓度更低且优于DNase。
要点
- P3001在临床前模型中显著减少肺黏液负荷,而NAC无效。
- NAC在CF患者中迅速从肺部清除,未改变痰液生物物理性质。
- P3001在CF痰液中起效比NAC更快、浓度更低,且优于DNase。
核心结论
- 降低气道黏液黏弹性是P3001类黏液溶解剂可实现的治疗目标。
研究设计与样本
- 临床前研究,采用生化与生物物理检测在体外、体内模型及患者痰液中测试药物疗效与毒性。
主要发现
- 二硫苏糖醇和P3001在体外均显示出优于NAC的还原活性。
- 在βENaC过表达小鼠中,P3001显著降低肺黏液负荷,而NAC无此作用(每组n=6-24只)。
- 在NAC治疗的CF受试者(n=5)中,雾化NAC迅速从肺部清除,未改变痰液生物物理性质。
- P3001起效比NAC更快、浓度更低,且在CF痰液体外实验中比DNase更有效。
临床怎么用
- P3001类黏液溶解剂可能为黏液阻塞性疾病提供比NAC更有效的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Airways obstruction with thick, adherent mucus is a pathophysiologic and clinical feature of muco-obstructive respiratory diseases, including chronic obstructive pulmonary disease, asthma, and cystic fibrosis (CF). Mucins, the dominant biopolymer in mucus, organize into complex polymeric networks via the formation of covalent disulfide bonds, which govern the viscoelastic properties of the mucus gel. For decades, inhaled N-acetylcysteine (NAC) has been used as a mucolytic to reduce mucin disulfide bonds with little, if any, therapeutic effects. Improvement of mucolytic therapy requires the identification of NAC deficiencies and the development of compounds that overcome them. OBJECTIVES: Elucidate the pharmacological limitations of NAC and test a novel mucin-reducing agent, P3001, in preclinical settings. METHODS: The study used biochemical (e.g., Western blotting, mass spectrometry) and biophysical assays (e.g., microrheology/macrorheology, spinnability, mucus velocity measurements) to test compound efficacy and toxicity in in vitro and in vivo models and patient sputa. MEASUREMENTS AND MAIN RESULTS: Dithiothreitol and P3001 were directly compared with NAC in vitro and both exhibited superior reducing activities. In vivo, P3001 significantly decreased lung mucus burden in βENaC-overexpressing mice, whereas NAC did not (n = 6-24 mice per group). In NAC-treated CF subjects (n = 5), aerosolized NAC was rapidly cleared from the lungs and did not alter sputum biophysical properties. In contrast, P3001 acted faster and at lower concentrations than did NAC, and it was more effective than DNase in CF sputum ex vivo. CONCLUSIONS: These results suggest that reducing the viscoelasticity of airway mucus is an achievable therapeutic goal with P3001 class mucolytic agents.
引用
- Ehre C, Rushton ZL, Wang B, et al. An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. Am J Respir Crit Care Med. 2019. PMID: 30212240. doi:10.1164/rccm.201802-0245OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。